Examining whether age restrictions on fertility treatment reflect science or social values
Dr Andrea Martani analyzes a survey showing public support for upper age limits on fertility treatment access, with respondents favoring thresholds between 40 and 50 years old. The article reveals significant variation across European countries, ranging from Denmark's 45-year cutoff to Greece's allowance up to 54 years. Martani questions whether these age restrictions are grounded in medical evidence or primarily reflect societal attitudes toward reproduction.
A July 2026 survey by PET and ESHRE examined public opinion across four European nations regarding embryo use in fertility treatment. The research revealed that most respondents favored establishing upper age boundaries for accessing fertility services, even when patients fund treatment privately. However, consensus on specific age thresholds proved elusive, with respondents clustering around 40, 45, and 50 years as preferred cutoffs.
The stark regulatory variation across Europe underscores the unresolved nature of age-based fertility restrictions. Denmark enforces a 45-year maximum for women, while Greece permits treatment through age 54—a gap of approximately nine years. Similar inconsistencies exist for partners, with France setting a 60-year limit and Albania a 50-year limit for non-birthing partners. This patchwork of legal frameworks demonstrates that age restrictions lack harmonized scientific grounding across jurisdictions.
This analysis could reshape discussions around fertility policy by challenging whether age limits rest on established medical evidence or predominantly reflect cultural values about reproductive timing. The findings may influence regulatory bodies reconsidering restrictive policies, potentially affecting access for older individuals seeking treatment. Healthcare policymakers might face pressure to either standardize restrictions based on clinical data or reconsider age as a primary access criterion, affecting reproductive autonomy discussions and resource allocation debates in fertility medicine.